Stock Price & Volume | Full Chart
EMAN, LYLT and SOPH among mid-day movers
Seeking Alpha News (Mon, 20-Mar 1:07 PM ET)
Acrivon Therapeutics stock plunges nearly 30%
Seeking Alpha News (Mon, 20-Mar 1:06 PM ET)
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Globe Newswire (Mon, 6-Mar 8:00 AM ET)
Acrivon Therapeutics to Participate on a Panel at Cowen's 43rd Annual Health Care Conference
Globe Newswire (Mon, 27-Feb 8:00 AM ET)
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.
As of March 20, 2023, ACRV stock price declined to $11.61 with 202,129 million shares trading.
ACRV has a market cap of $242.47 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ACRV belongs to (by Net Assets): IWM, IWN, IWO, IWC.
ACRV support price is $17.76 and resistance is $22.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV stock will trade within this expected range on the day.